Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials.

ABSTRACT:

Background

To determine how much an augmented analysis approach could improve the efficiency of prostate-specific antigen (PSA) response analyses in clinical practice. PSA response rates are commonly used outcome measures in metastatic castration-resistant prostate cancer (mCRPC) trial reports. PSA response is evaluated by comparing continuous PSA data (e.g., change from baseline) to a threshold (e.g., 50% reduction). Consequently, information in the continuous data is discarded. Recent papers have proposed an augmented approach that retains the conventional response rate, but employs the continuous data to improve precision of estimation.

Methods

A literature review identified published prostate cancer trials that included a waterfall plot of continuous PSA data. This conti

SUBMITTER: Grayling MJ 

PROVIDER: S-EPMC8793251 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature